Patient Characteristics at Transplant According to the CD34+ Cell Count Reinfused
| Characteristics . | Total Group (n = 168) . | CD34+ Cell Dose (×106/kg) . | ||
|---|---|---|---|---|
| ≤2.5 (n = 22) . | >2.5 and <15 (n = 105) . | ≥15 (n = 41) . | ||
| Median CD34+ cell count (×106/kg) | 6.86 | 1.5 | 5.85 | 21.6 |
| Range | 0.51-109 | 0.51-2.5 | 2.57-14.47 | 15.33-109 |
| Median MNC count (×108/kg) | 3.6 | 3.64 | 3.6 | 3.58 |
| Range | 0.17-22.4 | 0.53-22.4 | 0.17-15.51 | 0.57-7.34 |
| Line of treatment | ||||
| First line | 82 (49) | 7 (32) | 52 (50) | 23 (56) |
| Relapse | 86 (51) | 15 (68) | 53 (50) | 18 (44) |
| Patients with ≥3 previous regimens | 77 (46) | 15 (68) | 51 (49) | 11 (27)* |
| Patients with ≥6 months chemotherapy exposure | 76 (45) | 16 (73)* | 47 (45) | 13 (32) |
| Patients with >8 months alkylating agents | 32 (19) | 7 (32) | 20 (19) | 5 (12) |
| Patients with fludarabine | 18 (11) | 6 (27)* | 9 (9) | 3 (7) |
| Disease status at harvest | ||||
| CR | 47 (28) | 6 (27) | 30 (29) | 11 (27) |
| PR | 106 (63) | 13 (59) | 65 (62) | 28 (68) |
| SD | 14 (8) | 2 (9) | 10 (9) | 2 (5) |
| PD | 1 (1) | 1 (5) | — | — |
| Bone marrow at harvest | ||||
| Normal | 104 (62) | 10 (45) | 67 (64) | 27 (66) |
| Minimally infiltrated | 21 (12) | 3 (14) | 14 (13) | 4 (10) |
| Infiltrated | 41 (24) | 7 (32) | 23 (22) | 10 (24) |
| Not evaluated | 3 (2) | 2 (9) | 1 (1) | — |
| Characteristics . | Total Group (n = 168) . | CD34+ Cell Dose (×106/kg) . | ||
|---|---|---|---|---|
| ≤2.5 (n = 22) . | >2.5 and <15 (n = 105) . | ≥15 (n = 41) . | ||
| Median CD34+ cell count (×106/kg) | 6.86 | 1.5 | 5.85 | 21.6 |
| Range | 0.51-109 | 0.51-2.5 | 2.57-14.47 | 15.33-109 |
| Median MNC count (×108/kg) | 3.6 | 3.64 | 3.6 | 3.58 |
| Range | 0.17-22.4 | 0.53-22.4 | 0.17-15.51 | 0.57-7.34 |
| Line of treatment | ||||
| First line | 82 (49) | 7 (32) | 52 (50) | 23 (56) |
| Relapse | 86 (51) | 15 (68) | 53 (50) | 18 (44) |
| Patients with ≥3 previous regimens | 77 (46) | 15 (68) | 51 (49) | 11 (27)* |
| Patients with ≥6 months chemotherapy exposure | 76 (45) | 16 (73)* | 47 (45) | 13 (32) |
| Patients with >8 months alkylating agents | 32 (19) | 7 (32) | 20 (19) | 5 (12) |
| Patients with fludarabine | 18 (11) | 6 (27)* | 9 (9) | 3 (7) |
| Disease status at harvest | ||||
| CR | 47 (28) | 6 (27) | 30 (29) | 11 (27) |
| PR | 106 (63) | 13 (59) | 65 (62) | 28 (68) |
| SD | 14 (8) | 2 (9) | 10 (9) | 2 (5) |
| PD | 1 (1) | 1 (5) | — | — |
| Bone marrow at harvest | ||||
| Normal | 104 (62) | 10 (45) | 67 (64) | 27 (66) |
| Minimally infiltrated | 21 (12) | 3 (14) | 14 (13) | 4 (10) |
| Infiltrated | 41 (24) | 7 (32) | 23 (22) | 10 (24) |
| Not evaluated | 3 (2) | 2 (9) | 1 (1) | — |
Actual numbers are presented with percentages in parenthesis.
Abbreviation: MNC, mononuclear cells.
When the low or high groups were compared with the intermediate CD34+ group using the Pearson chi-squared test, onlyP values <.05 were considered as significant.